Trial pitches Triple-Threat chemo against rare, Fast-Moving cancer
NCT ID NCT04325425
Summary
This study is testing if a more intensive, three-drug chemotherapy regimen (mFOLFIRINOX) works better than the current standard two-drug treatment for people with a rare, fast-growing type of digestive cancer that has spread. Researchers will also analyze tumor samples to understand why some cancers respond better to certain treatments, aiming to personalize future care. The goal is to better control the cancer and help patients live longer without it getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH de Troyes
RECRUITINGTroyes, 10003, France
Contact Email: •••••@•••••
-
Centre Hospitalier de Saint Malo
RECRUITINGSt-Malo, 35403, France
Contact Email: •••••@•••••
-
Chu Dijon Bourgogne
RECRUITINGDijon, 21000, France
Contact Email: •••••@•••••
-
Chu de Caen
RECRUITINGCaen, 14033, France
Contact Email: •••••@•••••
-
Chu de Limoges - Dupuytren
RECRUITINGLimoges, 87042, France
Contact Email: •••••@•••••
-
Institut de Cancérologie de Bourgogne
RECRUITINGDijon, 21000, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.